"Vici Venous Stent Shows Good Primary Patency, Few MAE by 12 Months: VIRTUS" - Caitlin E. Cox
The Vici venous stent offers a high rate of primary patency and low rate of major adverse events (MAE) through 12-month follow-up, according to data from the VIRTUS pivotal study of patients with blockages in the iliofemoral venous outflow tract. “We’ve obviously all been looking forward to the introduction of a dedicated venous stent on the market,” said Robert Lookstein, MD (Icahn School of Medicine at Mount Sinai, New York, NY), when presenting the results last week at the International Symposium on Endovascular Therapy. Ideally, he said, a venous stent would be crush resistant, have enough flexibility to resist kink at physiological angles, be durable enough to endure shortening, twisting, and bending at the groin, deploy consistently, and show up on fluoroscopy, among other things.
— Robert Lookstein, MD, Professor, Radiology, Surgery, Icahn School of Medicine at Mount Sinai, Executive Vice Chair, Department of Diagnostic, Molecular, and Interventional Radiology, Mount Sinai Health System